A detailed history of Exodus Point Capital Management, LP transactions in Innoviva, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 267,665 shares of INVA stock, worth $5.18 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
267,665
Previous 284,215 5.82%
Holding current value
$5.18 Million
Previous $4.33 Million 1.36%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$14.4 - $16.4 $238,320 - $271,420
-16,550 Reduced 5.82%
267,665 $4.39 Million
Q1 2024

May 14, 2024

BUY
$14.56 - $16.78 $3.13 Million - $3.61 Million
215,292 Added 312.37%
284,215 $4.33 Million
Q3 2023

Nov 09, 2023

SELL
$12.37 - $13.89 $447,348 - $502,317
-36,164 Reduced 34.41%
68,923 $895,000
Q2 2023

Aug 10, 2023

SELL
$11.39 - $13.72 $1.73 Million - $2.09 Million
-152,219 Reduced 59.16%
105,087 $1.34 Million
Q1 2023

May 11, 2023

BUY
$10.73 - $13.6 $1.07 Million - $1.36 Million
100,140 Added 63.72%
257,306 $2.9 Million
Q4 2022

Feb 13, 2023

SELL
$11.8 - $13.78 $560,346 - $654,370
-47,487 Reduced 23.2%
157,166 $2.08 Million
Q3 2022

Nov 10, 2022

BUY
$11.61 - $15.22 $570,561 - $747,971
49,144 Added 31.6%
204,653 $2.38 Million
Q2 2022

Aug 19, 2022

BUY
$14.32 - $19.88 $1.24 Million - $1.72 Million
86,270 Added 124.6%
155,509 $2.3 Million
Q1 2022

May 13, 2022

BUY
$15.39 - $20.25 $755,402 - $993,951
49,084 Added 243.53%
69,239 $1.34 Million
Q4 2021

Feb 11, 2022

BUY
$15.91 - $18.72 $320,666 - $377,301
20,155 New
20,155 $348,000
Q4 2020

Feb 16, 2021

SELL
$9.33 - $12.48 $208,226 - $278,528
-22,318 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$10.33 - $14.49 $230,544 - $323,387
22,318 New
22,318 $233,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.35B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.